Voriconazole: A New Triazole Antifungal Agent

By M. Pearson, P. Rogers, John D Cleary, Stanley W. Chapman. The Annals of Pharmacotherapy, 2003

863 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/5afdc79252e15bb3115408687157c36b9a37b350

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Pfaller
2. D. Diekema
3. T. Walsh
4. Thierry Calandra
5. J. Guinea

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. J. Guinea

Citations in the corpus

• Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. (2008, background): “IDSA Guidelines for Blastomycosis • CID 2008:46 (15 June) • 1807 Because of nonlinear pharmacokinetics in adults and genetic differences in metabolism, there is both intrapatient and interpatient variability in serum voriconazole concentrations [47].”
• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “linear pharmacokinetics in adults and genetic differences in metabolism, there is both intrapatient and interpatient variability in serum voriconazole concentrations [115–118].”
• Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, background): “On the one hand, in recent years antifungal therapy options for both IC and IA have been expanded with the introduction of new agents that are effective and less toxic (29, 31, 32, 54, 100, 112, 123, 163, 184, 201, 275, 276, 326).”
• Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. (2014, background): “56 Voriconazole is a first-line agent for the treatment of invasive aspergillosis, invasive candidiasis caused by Candida spp. with reduced susceptibility to fluconazole, and serious infections caused by Scedosporium or Fusarium spp. 15 Voriconazole is the drug of choice for CNS aspergillosis.”
• Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). (2007, background): “eases [1–3]. Voriconazole has demonstrated efficacy and survival benefits over amphotericin B deoxycholate for the treatment of invasive aspergillosis, but it has numerous drug interactions and no activity against Zygomycetes, limiting its utility for this patient population [ 4 ].”
• Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. (2008, background): “, 40%–50%) is microbiologically active and available for penetration in infected organs [3, 8, 28, 29].”
• Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus (2004, background): “glabrata that are resistant to fluconazole (43); however, a strong positive correlation can be seen between voriconazole (R 0.”